Verastem logo

Verastem Share Price Today

(NASDAQ: VSTM)

Verastem share price is $6 & ₹521.81 as on 6 Mar 2025, 2.30 'hrs' IST

$6

0.1

(1.69%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Verastem share price in Dollar and Rupees. Guide to invest in Verastem stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Verastem, along with analyst recommendations, forecasts, and comprehensive financials.

Verastem share price movements

  • Today's Low: $5.80
    Today's High: $6.08

    Day's Volatility :4.61%

  • 52 Weeks Low: $2.10
    52 Weeks High: $13.52

    52 Weeks Volatility :84.47%

Verastem (VSTM) Returns

PeriodVerastem, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
14.29%
3.7%
0.0%
6 Months
150.0%
-2.8%
0.0%
1 Year
-52.72%
2.5%
0.0%
3 Years
466.04%
12.9%
-11.6%

Verastem (VSTM) Key Statistics

in dollars & INR

Previous Close
$5.9
Open
$6.0
Today's High
$6.08
Today's Low
$5.8
Market Capitalization
$262.6M
Today's Volume
$1.1M
52 Week High
$13.52
52 Week Low
$2.1
Revenue TTM
$10.0M
EBITDA
$-114.5M
Earnings Per Share (EPS)
$-3.34
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-136.87%

How to invest in Verastem Stock (VSTM) from India?

It is very easy for Indian residents to invest directly in Verastem from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Verastem stock in both Indian Rupees (INR) and US Dollars (USD). Search for Verastem or VSTM on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Verastem or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Verastem shares which would translate to 0.145 fractional shares of Verastem as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Verastem, in just a few clicks!

Returns in Verastem (VSTM) for Indian investors in Rupees

The Verastem stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Verastem investment value today

Current value as on today

₹52,230

Returns

₹47,770

(-47.77%)

Returns from Verastem Stock

₹52,719 (-52.72%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Verastem (VSTM)

-12%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Verastem Stock from India on INDmoney has decreased by -12% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Verastem

  • Balyasny Asset Management LLC

    8.87%

  • Nantahala Capital Management, LLC

    8.43%

  • Orbimed Advisors, LLC

    6.43%

  • AIGH Capital Management, LLC

    5.99%

  • BlackRock Inc

    5.49%

  • Vanguard Group Inc

    5.19%

Analyst Recommendation on Verastem

Buy

    92%Buy

    7%Hold

    0%Sell

Based on 14 Wall street analysts offering stock ratings for Verastem(by analysts ranked 0 to 5 stars)

Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Verastem Stock (VSTM)

What analysts predicted

Upside of 109.52%

Target:

$12.57

Current:

$6.00

Insights on Verastem Stock (Ticker Symbol: VSTM)

  • Price Movement

    In the last 3 years, VSTM stock has moved up by 445.5%
  • VSTM vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 119.2%
  • Price to Sales

    ForVSTM every $1 of sales, investors are willing to pay $18.1, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Verastem Technicals Summary

Sell

Neutral

Buy

Verastem is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Verastem (VSTM) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Verastem, Inc. logo
2.21%
150.0%
-52.72%
466.04%
108.33%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Verastem, Inc. logo
NA
NA
-1.89
-2.98
-1.37
-0.47
NA
0.28
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Verastem, Inc. logo
Buy
$262.6M
108.33%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Verastem

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Organization
Verastem
Employees
73
CEO
Mr. Daniel W. Paterson
Industry
Health Technology

Management People of Verastem

NameTitle
Mr. Daniel W. Paterson
President, CEO & Director
Mr. Daniel Calkins
CFO and Principal Accounting & Financial Officer
Dr. Robert A. Weinberg Ph.D.
Co-Founder & Chair of Scientific Advisory Board
Dr. Michelle Detwiler M.D., Ph.D.
Co-Founder
Mr. Matthew E. Ros
Chief Operating Officer
Dr. Jonathan Pachter Ph.D.
Chief Scientific Officer
Ms. Cathy Carew
Chief Organizational Effectiveness Officer
Mr. Nate Sanburn
Chief Business Officer
Mr. Michael Crowther
Chief Commercial & Strategy Officer
Ms. Colleen Mockbee
Global Head of Regulatory Affairs & Development

Important FAQs about investing in VSTM Stock from India :

What is Verastem share price today?

Verastem share price today stands at $6.00, Open: $6.00 ; Previous Close: $5.90 ; High: $6.08 ; Low: $5.80 ; 52 Week High: $13.52 ; 52 Week Low: $2.10.

The stock opens at $6.00, after a previous close of $5.90. The stock reached a daily high of $6.08 and a low of $5.80, with a 52-week high of $13.52 and a 52-week low of $2.10.

Can Indians buy Verastem shares?

Yes, Indians can invest in the Verastem (VSTM) from India.

With INDmoney, you can buy Verastem at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Verastem at zero transaction cost.

How can I buy Verastem shares from India?

It is very easy to buy Verastem from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Verastem (VSTM) be purchased?

Yes, you can buy fractional shares of Verastem with INDmoney app.

What are the documents required to start investing in Verastem stocks?

To start investing in Verastem, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Verastem Stock (VSTM)?

Today’s highest price of Verastem (VSTM) is $6.08.

Today’s lowest price of Verastem (VSTM) is $5.80.

What is today's market capitalisation of Verastem?

Today's market capitalisation of Verastem VSTM is 262.6M

What is the 52 Week High and Low Range of Verastem Stock (VSTM)?

  • 52 Week High

    $13.52

  • 52 Week Low

    $2.10

What are the historical returns of Verastem (VSTM)?

  • 1 Month Returns

    2.21%

  • 3 Months Returns

    150%

  • 1 Year Returns

    -52.72%

  • 5 Years Returns

    108.33%

Who is the Chief Executive Officer (CEO) of Verastem ?

Mr. Daniel W. Paterson is the current Chief Executive Officer (CEO) of Verastem.